FACC home

clinical team

clinical trials

treatment options

about cancer

ways to give

saying goodbye

CSU pet hospice

emotional support

related links

join our mailing list
join our mailing list
   
events calendar

There are no events to display for this time period.

Follow us on Facebook Veterinary Teaching Hospital
CSU Campaign
Advancing Cancer Treatment
 
| Share

CSU Animal Cancer Center Clinical Trial

Patient Disease:
Any Canine Neoplasia Accessible for Biopsy

Study Name:
Dasatinib Phase 1 Pharmacokinetics and Pharmacodynamics in Dogs

Purpose of the study:

  • To evaluate the safety, metabolism, and appropriate dosing of dasatinib in dogs
    • Dasatinib is an oral drug that inhibits the function of a group of proteins important for cancer growth called receptor tyrosine kinases

Primary Eligibility Criteria:

  • Dogs with a confirmed diagnosis of cancer that is > 2 cm in diameter and accessible for biopsy
  • 3-week washout from chemotherapy, 2 weeks from other tyrosine kinase inhibitors (e.g. Palladia), 6 weeks from radiation therapy, 72 hours from antacids (Pepcid, Prilosec, Tums)
  • Concurrent steroid therapy is allowed, but dogs must have been receiving steroids for at least three days (ideally a week) prior to the first therapeutic dose of dasatinib

Study Protocol:

  • Oral dasatinib given once daily at home

Owner Responsibilities:

  • Follow appointment schedule required by study protocol
  • Be comfortable administering oral medications
  • Costs of any ancillary medications given that are not related to side effects of the study drug

Financial Incentives:

  • Study pays for all costs associated with trial
  • $750 credit to VTH account which can be used for future treatment after completion of the trial

If you have further questions about any of our clinical trials, Please either login or sign up to submit a consulting form. Your consult will then be directed to an appropriate oncology clinician. Requests are typically returned within 5 business days